



# nci

## NORTHERN CLINICS OF İSTANBUL

VOL 10 • NO 3 • YEAR 2023



P ISSN 2148-4902

E ISSN 2536-4553

### Journal Abbreviation: North Clin Istanb

- Mentalization and Emotion regulation abilities in parents of children with nocturnal enuresis and its relationship with perceived caregiver burden
- Relationship between insight level and clinical and familial features in pediatric obsessive-compulsive disorder
- Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study
- Are follistatin-like protein 1 and follistatin-like protein 3 associated with inflammatory processes in patients with familial Mediterranean fever?
- Fibulin1 and mesothelin expressions in pancreas ductal adenocarcinoma
- The validity and reliability of Turkish adaptation of the Fear-Avoidance Beliefs Questionnaire in patients with neck pain
- Anti-mutated citrulline vimentin antibodies may be higher in Ankylosing spondylitis, but may not have a role in diagnosing disease and may not be associated with disease severity
- Oxidative stress, DNA damage, and inflammation in COVID-19 patients
- Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder
- Validation and reliability study of the Turkish version of the everyday cognition - 12 (T- ECog) scale

INDEXED IN WEB OF SCIENCE, EMERGING SOURCES CITATION INDEX, PUBMED, PUBMED CENTRAL, EUROPE PMC, EBSCO, DOAJ, ProQuest, TUBITAK TR INDEX, AND TURKIYE CITATION INDEX.



NORTHERN CLINICS OF ISTANBUL  
İSTANBUL KUZEY KLİNİKLERİ

## EDITOR-IN-CHIEF

Berna Terzioglu Bebitoglu, MD.

## EDITORS\*

Mustafa Aldag, MD.	Neslihan Buyukmurat, MD.	Betul Sozeri, MD.
Baris Murat Ayvaci, MD.	Tolga Canbak, MD.	Kemal Tekesin, MD.
Sema Basat, MD.	Azize Esra Gursoy, MD.	Ilkin Zindanci, MD.

## MANAGING EDITOR

Kemal Tekesin, MD.

## STATISTICAL EDITOR

Nurdan Colakoglu

## PUBLICATION COORDINATOR

Ahmet Keskin

## SCIENTIFIC COMMITTEE\*

Didem Tuba Akcali, MD.	Dilek Erdogan Ari, MD.	Zeid J. Khitan, MD.	Necdet Saglam, MD.
Ilknur Aktas, MD.	Yuksel Ersoy, MD.	Tayfun Kirazli, MD.	Abdurrahman Sahin, MD.
Mustafa Aldag, MD.	Duygu Geler Kulcu, MD.	Gurkan Kiran, MD.	Ilhan Sanverdi, MD.
Mustafa Aldemir, MD.	Kaan Gideroglu, MD.	Cemal Kocaaslan, MD.	Tarik Sapci, MD.
Orhan Alimoglu, MD.	Ahmet Gocmen, MD.	O. Emek Kocaturk Goncu, MD.	Ayşe Banu Sarifakioglu, MD.
Nuri Aydin, MD.	Mehmet Zafer Goren, MD.	Cevdet Ugur Kocogullari, MD.	Fatih Saygili, MD.
Ozlem Baysal, MD.	Aysegul Gunduz, MD.	Sukran Kose, MD.	Mehmet Selcuki, MD.
Basak Bilir Kaya, MD.	Ozlem Guneyssel, MD.	Turkan Kudsioglu, MD.	Ozlem Tanriovert, MD.
Hasan Bombaci, MD.	Melek Gura Celik, MD.	Carlo A. Mallio, MD.	Sait Terzi, MD.
Derya Buyukkayhan, MD.	Melih Atahan Guven, MD.	Kemal Memisoglu, MD.	Gulnur Tokuc, MD.
Mustafa Caliskan, MD.	Mert Ilker Hayiroglu, MD.	Aysel Milanlioglu, MD.	Filiz Topaloglu Demir, MD.
Kazim Capaci, MD.	Mine Hekimgil, MD.	Murat Muhcu, MD.	Ismail Turkmen, MD.
Turhan Caskurlu, MD.	Seyhan Hidioglu, MD.	Sait Naderi, MD.	Sezgin Vatansever, MD.
Ali Riza Cenk Celebi, MD.	Afitap Icagasioglu, MD.	Kemal Nas, MD.	Ayhan Verit, MD.
Beyhan Cengiz Ozyurt, MD.	Ates Kadioglu, MD.	Cagatay Nuhoglu, MD.	Destina Yalcin, MD.
Tongabay Cumurcu, MD.	Atila Karaalp, MD.	Tamer Okay, MD.	Tuba Yavuzsen, MD.
Seema Dayal, MD.	Ayşe Serap Karadag, MD.	Muhammed Fatih Onsuz, MD.	Sema Yilmaz, MD.
Gizem Dinler Doganay, MD.	Ihsan Muhammet Karaman, MD.	Melike Ozcelik, MD.	Ebru Zemheri, MD.
Sibel Dogan, MD.	Semra Kayatas Eser, MD.	Kamil Ozdil, MD.	
Mehmet Doganay, MD.	Umut Kefeli, MD.	H. Isin Ozisik Karaman, MD.	

\*The editorial board list is sorted alphabetically by surname.



NORTHERN CLINICS OF ISTANBUL  
İSTANBUL KUZEY KLİNİKLERİ

YEAR 2023

VOLUME 10

NUMBER 3

P ISSN 2148 - 4902

E ISSN 2536 - 4553

OWNERSHIP AND ACCOUNTABILITY FOR CONTENTS  
ON BEHALF OF THE ISTANBUL HEALTH DIRECTORATE

Kemal Tekesin, MD.

PUBLICATION MANAGER

Kemal Memisoglu, MD.

PUBLICATION COORDINATOR

Ahmet Keskin

EXECUTIVE OFFICE

Umraniye Teaching and Research Hospital  
Elmalikent Mah., Adem Yavuz Cad. No: 1, 34764 Umraniye, Istanbul-Turkiye  
Phone: +90 216 632 18 18  
Fax: +90 216 632 71 24  
<https://northclinist.com>  
e-mail: [bilgi@kuzeyklinikleri.com](mailto:bilgi@kuzeyklinikleri.com)

Indexed in Web of Science, Emerging Sources Citation Index, PubMed, PubMed Central, Europe PMC, DOAJ,  
ProQuest, TUBITAK TR Index, CLIO, CINAHL and Türkiye Citation Index.

PUBLISHER

KARE PUBLISHING  
Goztepe Mahallesi,  
Fahrettin Kerim Gokay Caddesi, No: 200,  
Daire: 2, Kadikoy, Istanbul, Turkiye  
Tel: +90 216 550 61 11  
Fax: +90 216 550 61 12  
<http://www.karepb.com>  
e-mail: [kare@karepb.com](mailto:kare@karepb.com)

PRESS

YILDIRIM PRINTING HOUSE  
Yuzyil Mah., Massit Matbaacılar Sitesi,  
1. Cad. No: 101, Bagcilar, Istanbul, Turkiye  
Tel: +90 212 629 80 37  
Fax: +90 212 629 80 39

Info

Press date: June 2023  
Circulation: 50  
Type of publication: Periodical

DESIGN

Ali Cangul  
[ali.cangul@karepb.com](mailto:ali.cangul@karepb.com)

ENGLISH EDITING BY

Sinjore Technologies

Northern Clinics of Istanbul (NCI) is a peer-reviewed journal published 6 issues in a year.  
Materials published in the Journal is covered by copyright ©2023 NCI. All rights reserved.  
This publication is printed on paper that meets the international standard ISO 9706:1994.  
National Library of Medicine recommends the use of permanent, acid-free paper in the production of biomedical literature.



## IV

## Instructions for the authors

## ORIGINAL ARTICLES

- 281–288**    **Mentalization and emotion regulation abilities in parents of children with nocturnal enuresis and its relationship with perceived caregiver burden**  
Toprak T, Ayribas B, Degirmentepe RB, Ozgur MO, Yilmaz M, Verit A
- 289–297**    **Relationship between insight level and clinical and familial features in pediatric obsessive-compulsive disorder**  
Miniksar DY, Oz B, Ozdemir M, Yuksel T
- 298–305**    **Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study**  
Cakan M, Ozdel S, Karadag SG, Ulu K, Cakmak F, Otur Yener G, Ozturk K, Baglan E, Sonmez HE, Demir F, Sozeri B, Aktay Ayaz N
- 306–313**    **Are follistatin-like protein 1 and follistatin-like protein 3 associated with inflammatory processes in patients with familial Mediterranean fever?**  
Kaplan H, Calis M, Yazici C, Gunturk I, Cuce I, Senel AS
- 314–321**    **Fibulin1 and mesothelin expressions in pancreas ductal adenocarcinoma**  
Aksoy A, Artas G, Kuloglu T, Koc M
- 322–327**    **The validity and reliability of Turkish adaptation of the Fear-Avoidance Beliefs Questionnaire in patients with neck pain**  
Ozuber B, Bas Aslan U, Ekici G
- 328–334**    **Anti-mutated citrulline vimentin antibodies may be higher in Ankylosing spondylitis, but may not have a role in diagnosing disease and may not be associated with disease severity**  
Sen N, Kacar C, Ozdem S, Uzun G, Tezcan ME
- 335–340**    **Oxidative stress, DNA damage, and inflammation in COVID-19 patients**  
Bektemur G, Bozali K, Colak S, Aktas S, Guler EM
- 341–344**    **Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder**  
Karaaslan Z, Yilmaz V, Yuceer H, Sanli E, Akcay HI, Kurtuncu M, Turkoglu R, Tuzun E
- 345–352**    **Validation and reliability study of the Turkish version of the everyday cognition - 12 (T- ECog) scale**  
Cinar N, Karali FS, Sahin S, Ates MF, Karsidag S
- 353–358**    **Mannose-binding lectin (MBL) levels in children with Hashimoto's thyroiditis**  
Gul A, Hatipoglu N, Yilmaz R, Ates HO
- 359–366**    **Neuropathic pain in patients with post-COVID-19**  
Comruk EB, Buyukavci R, Comruk E, Akturk S, Ersoy Y

- 367–377     Analysis of blood parameters and clinical features in women with pilonidal sinus disease: Is there a link between the disease and polycystic ovary syndrome?**

Yigit B, Liman RK, Kilicarslan G

- 378–384     Mean platelet volume as an effective biomarker for predicting high-risk patients of hereditary thrombophilia: A retrospective study**

Keski H

## CASE REPORTS

- 385–389     Anti-N-methyl D-aspartate receptor encephalitis presenting with the new-onset refractory status epilepticus**

Alemdar M, Acar T, Dalkilic S

- 390–392     Acanthosis nigricans or terra firma-forme dermatosis? Three adolescent cases**

Cebeci D, Cebeci Kahraman F

- 393–397     A pediatric case of Takayasu's arteritis with anti-neutrophil cytoplasmic antibody-associated vasculitis triggered by COVID-19 infection**

Caglayan S, Yener GO, Ulu K, Coskuner T, Guzel M, Kalin S, Yazan H, Erdogan S, Cakan M, Sozeri B

## LETTER TO THE EDITOR

- 398–400     Oral pulsed high-dose dexamethasone therapy for rheumatic diseases: An alternative safe and effective scheme**

de Carvalho JF, Skare T

**NORTHERN CLINICS OF ISTANBUL - NCI** is a peer-reviewed, open-access, international journal published by the Istanbul Provincial Health Directorate, Health Services Presidency (IHD). The NCI is printed 6 times a year. Free full-text articles in English are available at [www.kuzeyklinikleri.com](http://www.kuzeyklinikleri.com). The NCI is indexed in the Web of Science, Emerging Sources Citation Index, PubMed, PubMed Central, Europe PMC, DOAJ, ProQuest, CINAHL, ULAKBIM TR Index and Türkiye Citation Index. The journal publishes research, interesting case reports, letters to the editor, review articles, editorial comments, medical news, and guidelines. The NCI accepts manuscripts written in English. Opinions presented in published articles do not represent official endorsement of the IHD.

Manuscripts should be prepared in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, which is regularly updated by the International Committee of Medical Journal Editors (ICMJE), and available at <http://www.icmje.org>.

#### ARTICLE TYPES

The NCI publishes the kinds of articles briefly described below.

**Research Articles:** These are articles on original clinical (conducted with healthy subjects or patients) or experimental (human, animal or in-vitro trials) research performed in all fields.

**Case Reports:** This section contains reports on interesting, instructive or rarely seen cases.

**Review Articles:** Reviews are usually written at the invitation of the editors. The NCI publishes clinical review articles related to the natural course of diseases, updated diagnostic and therapeutic approaches of concern to clinicians and specialists in basic sciences that encompass genetic, physiological, and pharmacological aspects of the underlying mechanisms of diseases, and reviews about state-of-the-art treatment strategies, technological advancements, and newly approved drugs.

**Editorial Comments:** This section contains editors' comments, reviews, and other relevant items.

**Letters to the Editor:** These are comments, criticism and contributions in response to a paper published in the NCI. The author(s) of a criticized article has the right to reply. The article that is the subject of the comments should be listed in the references section. Letters must be sent to the editor within 4 weeks following publication of the subject article in the NCI.

#### PREPARATION OF MANUSCRIPT

**General Format:** All manuscripts should be typewritten on A4 white paper, and 2.5 cm-wide margins should be left on all sides. The references should be numbered consecutively in the order of their first mention in the text. All text material, including references, footnotes, and table and figure legends, should be typed using double-spacing in an 11 point font with left alignment and without hyphenated line breaks. The fonts Times New Roman or Arial should be used in the text, for symbols, and all other special characters. Please use the editing features of your word processing program to type bold or italic letters, mathematical symbols, Greek letters, subscript and superscript characters. Please take care not to confuse the letters O and I with the numerals 0 and 1. To set a left indent for a paragraph, click the TAB button once. Only the International System of Units (SI) should be used for units of measurement. Abbreviations and acronyms should be written in parentheses following the full name or an explanation of the usage should be provided just after the first appearance in the text. Please review the final version of the manuscript very carefully, especially for formatting and editing errors.

All pages of the manuscript should be consecutively numbered starting from the title page (page 1, title page; page 2, Turkish abstract; page 3, English abstract, etc.). Page numbers should be indicated on the upper right-hand corner of each page. Final version of the manuscript should be in ".doc" or ".rtf" format. Manuscripts submitted in ".pdf" format will not be accepted.

**Manuscript Sections:** All research articles must contain the following sections: (1) Title page, (2) Abstract with

keywords, (3) Introduction, (4) Methods, (5) Results, (6) Discussion, (7) Acknowledgements, (8) Conflict of interest, (9) Funding resources, (10) References, (11) Legends of the figures, (12) Tables, (13) Figures. In case of need, presentation of Methods, Results, and Discussion sections under subheadings is preferred. Case reports should be presented following abstract section, under headings of introduction, case presentation, and discussion. In review articles, appropriate headings can be used in accordance with the development of the manuscript. Sections of the manuscript in order of their appearance in the text with relevant explanations are listed below.

**Title Page:** The title page should contain the following information: (1) article title, (2) full name and academic title of all participating authors, (3) department and institution of all authors, including the city and country, (4) name, full mailing address, phone and fax numbers, and e-mail address of the corresponding author, and (5) word count (including title page, abstracts, explanatory notes for figures and tables). If the study was presented elsewhere, those details should be indicated on the title page.

Authors should disclose whether they used artificial intelligence (AI)-assisted technologies (such as Large Language Models [LLMs], chatbots, or image creators) in the production of submitted work. Authors should assert that there is no plagiarism in their paper, including in text and images produced by the AI-if any- and must ensure there is appropriate attribution of all quoted material, including full citations.

**Abstract:** The abstract should be written on a separate page. It should contain at most 250 words, and be structured as follows: (1) Objective, (2) Methods, (3) Results, and (4) Conclusion. Under these headings, briefly describe the subject of the article, methods used for the study, basic findings, and author's conclusion. No subtitles may be used in the abstract of a case report. A minimal number of abbreviations and/or acronyms should be used. Abstracts should not contain any references. A maximum of 5 key-



words should be included at the end of the abstract. The Medical Subject Headings (MeSH) prepared by the US National Library of Medicine (NLM) may be used as a reference for keywords.

**Introduction:** State the specific purpose and available data relevant to the study.

**Methods:** All methods used to select participants and conduct the study should be described in detail. Known methods should be cited. Novel or modified methods used should be described in detail. Doses, concentrations, routes, and duration of administration of drugs and chemical agents should be indicated. A concise report of all statistical methods used for summarizing available data and for testing the proposed hypothesis should be provided under a subtitle, including the p value criteria determined for statistically significant difference. Statistical evaluation conducted should be explained in detail. Standard statistical methods should be used as much as possible. If rarely employed or novel statistical methods were used, then the relevant references should be cited. When necessary, more detailed explanations about unusual, complex or new statistical methods can be provided in separate files for readers as online supplementary data. The commercial name and version number of any statistical software package program used should be provided. For statistical evaluation, the recommendations in the statistics section of the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication" (<http://www.ICMJE.org>) should be taken into consideration.

**Results:** The study results should be presented in logical sequence and in detail. The findings should be supported by figures and tables. Information given in figures and tables should not be repeated in the text unless absolutely required.

**Discussion:** Data relevant to the study subject matter should be examined, evaluated, and substantiated with references from domestic and international sources. General information irrelevant or superfluous to the report should not be included.

**Acknowledgement:** The names of individuals who contributed to the study but who fail to meet the criteria of authorship should be mentioned in this section. The written consent of all individuals mentioned should be obtained.

**Conflict of Interest:** All potential conflicts of interest should be declared under this heading. All affiliations with pharmaceutical firms, biomedical device manufacturers, and other service or product procurers relevant to the subject matter of the study should be explicitly indicated. If no conflict of interest exists, this should be stated as "none declared." Declarations related to conflicts of interest should be placed at the bottom of a separate page after the acknowledgements and before the references. A Conflict of Interest Form will be sent to the authors of accepted papers.

**Funding sources:** The full name of any sponsoring foundation or institution should be provided.

**References:** References should be listed consecutively in the order of their first appearance in the text. All sources the authors made direct use of should be included as references, excluding unpublished results and personal communications. During the preparation of the manuscript for publication, additional information regarding any unconfirmed references will be requested from the authors. Titles of journals should be abbreviated as indicated in the Index Medicus. If that is not possible, then the full name of the journal should be provided. In the references, a maximum of 6 authors should be cited for any 1 article with their full surname, and then the initial(s) of their first name. If more than 6 authors contributed to the cited article, then after the name of the sixth author, the abbreviation "et al." should be added to indicate that there are additional authors. The notation and listing of references should comply with the following sample reference citations:

1. Journal: Balci NC, Sirvanci M, Tufek I, Onat L, Duran C. Spontaneous retroperitoneal hemorrhage secondary to subcapsular renal hematoma: MRI findings. *Magn Reson Imaging* 2001;19:1145-8.

2. Articles in press: Roten L, Derval N, Sacher F, Pascale P, Wilton SB, Scherr D, et al. Ajmaline attenuates electrocardiogram characteristics of inferolateral early repolarization. *Heart Rhythm* 2011 Sep 19 [E-pub ahead of print], doi:10.1016/j.hrthm.2011.09.013.
3. Book: Brown AM. *Physiology of the liver*. 3<sup>rd</sup> ed. Philadelphia: Lippincott Williams & Wilkins; 2003.
4. Chapter in book: Anderson JL, Muhlestein JB. The role of infection. In: Theroux P, editor. *Acute coronary syndromes: a companion to Braunwald's Heart Disease*. Philadelphia: W.B. Saunders; 2003. p. 88-107.
5. Web page: Nainggolan L. New salt paper causes controversy. *Heartwire*. May 3, 2011. Available at: <http://www.theheart.org/article/1220043.do>. Accessed: June 12, 2011.

**Figure Legends:** Explanatory notes for each figure should be submitted on a separate page in order of their appearance in the text immediately after the references section under the heading "figure legends." All abbreviations and symbols used in the figure should be defined in alphabetical order.

**Figures:** The manuscript will not be evaluated until all figures cited in the text are submitted. The number of figures provided should be in accordance with the content and data presented in the text, and table data should not be repeated in figures. All figures should be sent in individual electronic file format ready for publication with maximum dimensions of 125 cm x 180 cm. Illustrations in color should be in CMYK format and have a minimum resolution of 300 DPI suitable for publication. Figures depicted in gray scale should have a minimum resolution of 600 DPI, and the minimum resolution required for black and white illustrations is 1200 DPI. All figures should be in TIFF format. Figures must not disclose or imply the identity of a specific individual without the written consent of the individual in question.

**Tables:** Each table should be typed or printed with double-spacing on a separate sheet of paper. Tables should be numbered consecutively in the order

of their first citation in the text. The number and title of the table should be placed just above the table. Do not use vertical lines between columns. Horizontal lines should be used only above and below the headings of the columns, and at the bottom of the table. If required, explanatory notes regarding table data should be written in footnotes. All abbreviations and acronyms used in the table should also be explained in alphabetical order in footnotes.

## ETHICAL POLICY

NCI follows the ethics flowcharts developed by the Committee on Publication Ethics (COPE) for dealing with cases of possible scientific misconduct and breaches of publication ethics. For detailed information please visit [www.publicationethics.org](http://www.publicationethics.org).

All submitted manuscripts are screened with plagiarism software (iThenticate) to detect instances of overlapping and similar text during the evaluation process.

All manuscripts presenting data obtained from research involving human subjects must include a statement that the written informed consent of the participants was obtained and that the study was approved by an institutional review board or an equivalent body. This institutional approval should be submitted with the manuscript. Authors of case reports must submit the written informed consent of the subject(s) of the report or of the patient's legal representative. Manuscripts with human and animal studies should describe the steps taken to eliminate pain and suffering.

## AUTHORSHIP

All individuals listed as "author" in the submitted manuscript must make an adequate contribution to the study, meet the criteria of authorship, and take responsibility for their part of the manuscript. For the sake of the outcomes and the integrity of the study, at least one author should be responsible for each section of the manuscript. All authors mentioned in the cover letter must meet all of the following criteria: (1) substantial contribution to conception, design of the study, analysis, and

interpretation of data, or all of these criteria; (2) significant contribution to the drafting of the article or revision of its scientific content; (3) approval of the final version of the article to be published.

In multicentered studies, all individuals who are named as authors under the title of the article should meet all the above-mentioned requirements of authorship. Seeking or providing financial support for the study, and/or data collection do not satisfy the criteria of authorship per se, nor does general support or guidance provided to the study investigators. Individuals who contributed to the study in various ways but who fail to meet the criteria of authorship may be included in the acknowledgements with their written consent. Please refer to the ICMJE website for more information about authorship. Increasing the number of authors unnecessarily is not ethical conduct and to prevent any attempt to seek undue academic prestige or other unethical advantages, the editor may request a declaration from the authors of their individual contributions to the article and publish this information, if deemed appropriate. The sequence of authors' names should be based on a consensus reached by all the participating authors. Due to different specifications for the sequencing of authors, the order provided will be used unless otherwise stated. Authors may explain the rationale for a different sequence in a footnote.

## DECLARATION OF ARTIFICIAL INTELLIGENCE (AI)-ASSISTED TECHNOLOGY IN SCIENTIFIC WRITING

At submission, authors should disclose whether they used artificial intelligence (AI)-assisted technologies (such as Large Language Models [LLMs], chatbots, or image creators) in the production of submitted work. Authors who use such technology should describe, in both the Title Page and the submitted work, how they used it. Chatbots (such as ChatGPT) and AI assisted technologies should not be listed as an author or co-author nor cited because they cannot be responsible for the accuracy, integrity, and originality of the work, and

these responsibilities are required for authorship. Therefore, humans are responsible for any submitted material that included the use of AI-assisted technologies. Authors should carefully review and edit the result because AI can generate authoritative-sounding output that can be incorrect, incomplete, or biased. Authors should be able to assert that there is no plagiarism in their paper, including in text and images produced by the AI. Humans must ensure there is appropriate attribution of all quoted material, including full citations.

## COVER LETTER

Each manuscript should be sent with a cover letter that must contain the following explicit declarations: (1) all authors meet the criteria of authorship; (2) the submitted manuscript was not simultaneously sent to another journal and it is not presently being evaluated by another journal; (3) no part of the content of the manuscript has been previously published elsewhere; and (4) the manuscript has been read and approved of by all authors. The name, full address, phone and fax number(s), and e-mail address of the corresponding author to whom all editorial correspondence will be directed must be provided. A brief paragraph describing the scientific significance of the manuscript may also be included.

## SUBMISSION OF THE MANUSCRIPT

All manuscripts should be submitted to the NCI via the online submission system. All authors' ORCID numbers need to be submitted when creating an account for correspondence. To obtain an ORCID number, please visit: <https://orcid.org/> For questions or requests related to the submission and evaluation process of manuscripts, the editorial office may be contacted by e-mail at [bilgi@kuzeyklinikleri.com](mailto:bilgi@kuzeyklinikleri.com). In compliance with the journal's publication rules, the current status of the manuscript will not be discussed on the phone prior to acceptance for publication. First-time users of the online submission system will need to register. A user name and a code specific to the user will be sent by e-mail. For further details please consult the online manuscript submission page.



### REVIEW OF MANUSCRIPTS

In order for an article to be published in the journal it should not be published elsewhere, and must be deemed suitable for publication by the editorial board selected by the NCI Executive Committee. All responsibility for the manuscript belongs to the author(s). The evaluation process of the submitted manuscript will not begin until a document with the signed approval of all authors has been received. During typesetting and other preparation of the manuscript for publication, a Copyright Transfer Form will be sent to the primary author(s) ("guarantors") who will assume responsibility for the manuscript. All submitted manuscripts are first evaluated by the editorial board. At this stage, manuscripts not deemed suitable for publication in NCI, including those not complying with the requirements or without adequate scientific

content, will be returned to the authors. Manuscripts found suitable for publication will be sent to reviewers for more detailed evaluation. Acceptability of manuscripts is dependent on originality, scientific content, and the subject of the study, in accordance with the publication protocol of the journal. All research articles deemed suitable for publication are subjected to a detailed statistical evaluation. The authors are informed of the editors' decision on the acceptability of the manuscript via e-mail, usually within 6 weeks of its submission. The editors do not discuss their decision on the phone. All objections and requests should be communicated to the editors in a written format. If deemed necessary, the editorial board has the right to make modifications to the text without altering the main concept of the manuscript. An offprint of the manuscript will not be sent to the author(s).

### OPEN ACCESS

NCI is a fully open access journal. All articles published in NCI are available on the internet to all users immediately upon publication. Non-commercial use and distribution in any medium is permitted, provided the author and the journal are properly credited.

### EDITORIAL PROCESSING CHARGE

This journal assesses no submission fees, publication fees (article processing charges), or page charges.

### ADDRESS OF CORRESPONDENCE

KARE PUBLISHING

Goztepe Mahallesi, Fahrettin Kerim Gokay Caddesi, No: 200, Daire: 2, Kadikoy, Istanbul, Turkiye

Tel: 0216 550 61 11

Fax: 0216 550 61 12

E-mail: kare@karepb.com